Table 3.
Median survival comparison between the discordant and concordant groups according to receptor profiles in patients with primary breast cancer and brain metastasis
| Median survival (months) | Log-rank test (p value) | |
|---|---|---|
| ER conversion | 0.853 | |
| Discordant (n = 2) | 4.9 | |
| Concordant (n = 19) | 22.8 | |
| PR conversion | 0.310 | |
| Discordant (n = 8) | 15.4 | |
| Concordant (n = 13) | 30.1 | |
| HER2 conversion | 0.389 | |
| Discordant (n = 5) | 21.4 | |
| Concordant (n = 16) | 22.8 |
ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor 2